Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 11:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 4,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Assessment Only Control Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Forms of Racial Discrimination Study

NCT03720600
View directory record Official record
Conditions
Psychological Distress
Interventions
MAB Intervention
Behavioral
Lead sponsor
University of Massachusetts, Boston
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

NCT01955707
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 85 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
San Diego, California • Gainesville, Florida • Kansas City, Kansas + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2016 · Synced Oct 28, 2026, 11:35 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial

NCT05159765
View directory record Official record
Conditions
Myopia
Interventions
Single vision contact lenses, Multifocal contact lenses
Device
Lead sponsor
Visioneering Technologies, Inc
Industry
Eligibility
7 Years to 13 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
4
States / cities
Fresno, California • Deerfield, Illinois • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato® Granisetron Single Dose PK

NCT04200092
View directory record Official record
Conditions
Healthy
Interventions
0.5mg AZ-010; placebo, 1mg AZ-010, 3mg AZ-010, AZ-010 1mg, IV Granisetron 1mg, Placebo
Combination Product · Drug · Other
Lead sponsor
Nova Pneuma Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days

NCT04022889
View directory record Official record
Conditions
Healthy
Interventions
INTERCEPT Treated Platelets
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Cincinnati, Ohio • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 28, 2026, 11:35 PM EDT
Recruiting Phase 2 Interventional

Milk Thistle Clinical Trial in Pediatric NAFLD

NCT06477146
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD)
Interventions
Milk thistle (MT), Placebo, Lifestyle Modification, Fibroscan
Drug · Behavioral · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
9 Years to 22 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 28, 2026, 11:35 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Strategies for Recovery of Dexterity Post Stroke

NCT01977027
View directory record Official record
Conditions
Stroke With Hemiparesis
Interventions
Alternate Hand Training or Affected Hand Training
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 75 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914

NCT01929629
View directory record Official record
Conditions
Gonococcal (GC) Infection
Interventions
Part A, Part B
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Oct 28, 2026, 11:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

NCT07540910
View directory record Official record
Conditions
Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Interventions
EDP-978, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing Brief Personalized Feedback Integrating Lab-based Alcohol Cue Information

NCT05873556
View directory record Official record
Conditions
Alcohol Consumption
Interventions
Lab-based Cue Reactivity Personalized Feedback Intervention (PFI)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 24 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2B Study to Evaluate the Efficacy of Bentracimab (PB2452) in Reversal of Ticagrelor in Subjects Aged 50-80 Years Old

NCT04122170
View directory record Official record
Conditions
Healthy
Interventions
Ticagrelor Oral Tablet - Pre-Treatment, Aspirin (ASA) Oral Tablet - Pre-Treatment, Bentracimab (PB2452) Infusion, Placebo (0.9% Sodium chloride) infusion
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
13
States / cities
Rogers, Arkansas • Cypress, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 28, 2026, 11:35 PM EDT
Recruiting Phase 3 Interventional

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07355218
View directory record Official record
Conditions
Systematic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Interventions
Enpatoran, Placebo, Standard of care (SoC)
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Upland, California • DeBary, Florida • Fort Lauderdale, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 28, 2026, 11:35 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation Of PF-00572778 And Alprazolam On Naloxone Challenge In Healthy Subjects

NCT00580190
View directory record Official record
Conditions
Healthy
Interventions
alprazolam, Placebo, PF-00572778
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 14, 2009 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pilot Evaluation of Two Test Materials With a Positive Control When Used as a Patient Preoperative Skin Preparation

NCT03861780
View directory record Official record
Conditions
Bacteria Microflora Reduction
Interventions
Project X 26ml, Project X 5.1ml, Prevantics Maxi Swabstick
Drug
Lead sponsor
Professional Disposables International, Inc.
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Oct 22, 2021 · Synced Oct 28, 2026, 11:35 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)

NCT02945046
View directory record Official record
Conditions
Episodic Cluster Headache
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Phoenix, Arizona • Canoga Park, California • Santa Monica, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose

NCT06908954
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
Palovarotene
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of Vimseltinib on Pharmacokinetics of Combined Oral Contraceptive (Ethinyl Estradiol/Levonorgestrel)

NCT07539090
View directory record Official record
Conditions
Healthy Participants
Interventions
Vimseltinib, Combined Oral Contraceptive (COC) (ethinyl estradiol [EE]/levonorgestrel [LNG])
Drug
Lead sponsor
Deciphera Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Not applicable Interventional

Stigma and Online Counseling to Increase HIV/STI Testing

NCT03107910
View directory record Official record
Conditions
HIV/STI Testing
Interventions
Stigma and Structural Interventions, Health Information Seeking
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years and older · Male only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 2 Interventional Results available

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

NCT00862459
View directory record Official record
Conditions
Brain Diseases, Spinal Cord Diseases
Interventions
Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875), OptiMARK~0.1 mmol/kg BW
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
20
States / cities
Sacramento, California • San Diego, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 3 Interventional Results available

Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza

NCT02369159
View directory record Official record
Conditions
Influenza
Interventions
Peramivir, Oseltamivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
0 Days to 17 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Shreveport, Louisiana • Dayton, Ohio • Smithfield, Pennsylvania + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

NCT02612662
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
AZD4076, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Not applicable Interventional

BMI Screening and Reporting in Schools: The Fit Study

NCT02088086
View directory record Official record
Conditions
Pediatric Obesity, Overweight
Interventions
BMI screening, BMI reporting, Fitness testing
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
7 Years and older
Enrollment
36,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 28, 2026, 11:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of the Impact of Vitrification on Oocytes

NCT01223118
View directory record Official record
Conditions
Fertilization
Interventions
Vitrification and PGD
Procedure
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 35 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Morristown, New Jersey • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Oct 28, 2026, 11:35 PM EDT
Recruiting Not applicable Interventional

Effects of Myoelectric Channel Count and Targeting for Upper Limb Prosthetic Control

NCT07011420
View directory record Official record
Conditions
Amputation, Amputation, Traumatic, Amputation, Congenital, Prosthesis User, Upper Limb Amputation Below Elbow (Injury), Amputation; Traumatic, Arm: Forearm, Between Elbow and Wrist
Interventions
Experimental socket with 4 untargeted channels active, Experimental socket with 8 untargeted channels active, Experimental socket with up to 16 untargeted channels active, Experimental socket with 8 targeted channels active, Coapt EMG Cuff
Device
Lead sponsor
Liberating Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Holliston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 28, 2026, 11:35 PM EDT